FibroBiologics, Inc. financial data

Symbol
FBLG on Nasdaq
Location
455 E. Medical Center Blvd, Suite 300, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Jul 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 109 %
Debt-to-equity 502 %
Return On Equity -609 % +56.7%
Return On Assets -101 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.9M shares +19.1%
Entity Public Float 147M USD
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 38.6M shares +18.1%
Weighted Average Number of Shares Outstanding, Diluted 38.6M shares +18.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.39M USD +94.9%
General and Administrative Expense 9.69M USD +22.3%
Operating Income (Loss) -16.1M USD -43.5%
Nonoperating Income (Expense) 2.85M USD
Net Income (Loss) Attributable to Parent -13.2M USD +32.1%
Earnings Per Share, Basic 0 USD/shares +45.5%
Earnings Per Share, Diluted 0 USD/shares +45.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.85M USD +48.1%
Other Assets, Current 18K USD 0%
Assets, Current 10.2M USD +56.4%
Property, Plant and Equipment, Net 967K USD +21%
Operating Lease, Right-of-Use Asset 2.71M USD +69.2%
Assets 13.9M USD +56%
Contract with Customer, Liability, Current 241K USD
Liabilities, Current 11M USD +8.21%
Operating Lease, Liability, Noncurrent 2.08M USD +78.5%
Liabilities 13M USD +15.5%
Retained Earnings (Accumulated Deficit) -45.1M USD -41.4%
Stockholders' Equity Attributable to Parent 860K USD
Liabilities and Equity 13.9M USD +56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.28M USD -23.4%
Net Cash Provided by (Used in) Financing Activities 3.28M USD -77.5%
Net Cash Provided by (Used in) Investing Activities -43K USD -438%
Common Stock, Shares Authorized 300M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.32M USD -429%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.85M USD +48.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4K USD
Deferred Tax Assets, Valuation Allowance 5.26M USD +79.1%
Deferred Tax Assets, Gross 5.68M USD +70.7%
Operating Lease, Liability 2.71M USD +75%
Depreciation 198K USD +70.7%
Payments to Acquire Property, Plant, and Equipment 43K USD +438%
Lessee, Operating Lease, Liability, to be Paid 3.12M USD +77.1%
Property, Plant and Equipment, Gross 1.28M USD +39.9%
Operating Lease, Liability, Current 627K USD +64.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 886K USD +62.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 790K USD +61.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 405K USD +92.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 576K USD +13.2%
Deferred Tax Assets, Operating Loss Carryforwards 3.61M USD +80.2%
Preferred Stock, Shares Authorized 10M shares -50%
Lessee, Operating Lease, Liability, to be Paid, Year Four 351K USD
Additional Paid in Capital 46M USD +55.8%
Share-based Payment Arrangement, Expense 2.44M USD +26.6%
Interest Expense 5K USD -50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares